TP53 and hepatocellular carcinoma: Moreover, according to the results of our clinical cohorts, although HCC patients with p53-wild type had a better clinical outcome than p53-mutation group when treated with sorafenib-based therapy, higher levels of URI in the p53-wild type group still indicated worsen prognosis.